Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Tai

Showing results (251-260 of 278) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid TumorsGiuseppe Curigliano, Hans Curigliano, Nicolas Mach, et al.
NPJ Precision Oncology|February 11, 2026
Innate lymphoid cell heterogeneity and etiology-specific reprogramming in hepatocellular carcinomaYun Hua Lee, Samuel Chuah, Wei Qiang Leow, et al.
Liver Cancer|September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and TaiwanThomas Yau, David Tai, Stephen Lam Chan, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Nature Medicine|February 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung-Don Kim, Seyoung Jung, Ho Yeong Lim, et al.
Plos Computational Biology|February 18, 2025
Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironmentMai Chan Lau, Jennifer Borowsky, Juha P Väyrynen, et al.
Journal of Gastrointestinal Oncology|November 12, 2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registryFaisal Hayat, Simon Chiu, Ashleigh Stuart, et al.
Nature Nanotechnology|August 6, 2021
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinaseXiming Shao, Zhihao Ding, Wenhua Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaEytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Frontiers in Immunology|June 21, 2023
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinomaChun Chau Lawrence Cheung, Yong Hock Justin Seah, Juntao Fang, et al.
Pageof 28

Showing results (251-260 of 278) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid TumorsGiuseppe Curigliano, Hans Curigliano, Nicolas Mach, et al.
NPJ Precision Oncology|February 11, 2026
Innate lymphoid cell heterogeneity and etiology-specific reprogramming in hepatocellular carcinomaYun Hua Lee, Samuel Chuah, Wei Qiang Leow, et al.
Liver Cancer|September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and TaiwanThomas Yau, David Tai, Stephen Lam Chan, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Nature Medicine|February 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung-Don Kim, Seyoung Jung, Ho Yeong Lim, et al.
Plos Computational Biology|February 18, 2025
Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironmentMai Chan Lau, Jennifer Borowsky, Juha P Väyrynen, et al.
Journal of Gastrointestinal Oncology|November 12, 2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registryFaisal Hayat, Simon Chiu, Ashleigh Stuart, et al.
Nature Nanotechnology|August 6, 2021
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinaseXiming Shao, Zhihao Ding, Wenhua Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaEytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Frontiers in Immunology|June 21, 2023
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinomaChun Chau Lawrence Cheung, Yong Hock Justin Seah, Juntao Fang, et al.
Pageof 28